← 返回

下一代肿瘤疫苗与新兴免疫治疗联合方案

英文原题:Next-generation cancer vaccines and emerging immunotherapy combinations.

查看英文原题

Next-generation cancer vaccines and emerging immunotherapy combinations.

PubMed 2024/07/23(内容时间) Trends Cancer Q1 · IF 21.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

治疗性癌症疫苗数十年来一直被研究,目标是诱导持久有效的抗肿瘤免疫反应,使肿瘤消退、阻止进展并清除微小残留病,同时避免严重不良反应。新型疫苗技术及抗原预测方法已显著提高疗效,但成功临床应用仍需克服肿瘤介导的免疫抑制和逃逸机制。本文介绍治疗性癌症疫苗,并讨论新一代疫苗与现有免疫疗法的联合策略,尤其是免疫检查点抑制剂及过继细胞/细胞治疗。

展开英文摘要原文

Therapeutic cancer vaccines have been a subject of research for several decades as potential new weapons to tackle malignancies. Their goal is to induce a long-lasting and efficient antitumour-directed immune response, capable of mediating tumour regression, preventing tumour progression, and eradicating minimal residual disease, while avoiding major adverse effects. Development of new vaccine technologies and antigen prediction methods has led to significant improvements in cancer vaccine efficacy.

However, for their successful clinical application, certain obstacles still need to be overcome, especially tumour-mediated immunosuppression and escape mechanisms. In this review, we introduce therapeutic cancer vaccines and subsequently discuss combination approaches of next-generation cancer vaccines and existing immunotherapies, particularly immune checkpoint inhibitors (ICIs) and adoptive cell transfer/cell-based immunotherapies.

论文信息

作者
Brandenburg A、Heine A、Brossart P
第一作者单位
Medical Clinic III of Oncology, Hematology, Rheumatology and Immune-Oncology, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany.Germany
通讯作者单位
Medical Clinic III of Oncology, Hematology, Rheumatology and Immune-Oncology, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany. Electronic address: Peter.Brossart@ukbonn.de.Germany
文献类型
综述
期刊
Trends in cancer2024 Aug
原文标识
PubMed 39048489 · DOI 10.1016/j.trecan.2024.06.003